Neolab Multihaler

**Neolab Multihaler** is a fixed-dose, dry-powder inhaler containing **fluticasone propionate** and **salmeterol** that was developed by Neolab as a generic version of the fluticasone propionate/salmeterol reference dry-powder inhaler Seretide Accuhaler. Fluticasone propionate is an inhaled corticosteroid that activates the glucocorticoid receptor to suppress airway inflammation, while salmeterol is a long-acting selective beta-2 adrenergic receptor agonist that produces sustained bronchodilation. The product was evaluated for asthma in a Phase III crossover study in pre-pubertal children, including assessment of short-term linear growth and hypothalamic-pituitary-adrenal-axis effects versus Seretide Accuhaler. ([clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005828-14/DK))